Carboplatin, ifosfamide, and etoposide chemotherapy for extensive-disease small cell lung cancer.
- Author:
Hee Juang RYU
1
;
Young Nam KIM
;
Seon Yeong GYEONG
;
Se Hoon PARK
;
Chang Hyeok AN
;
Soo Mee BANG
;
Sang Pyo LEE
;
Jae Ik LEE
;
Jeong Ung PARK
;
Eun Kyung CHO
;
Seong Hwan JEONG
;
Dong Bok SHIN
;
Jae Hoon LEE
Author Information
1. Division of Hematology and Oncology, Gachon Medical School Gil Medical Center, Incheon, Korea. ekcho7@hanmail.net
- Publication Type:Original Article
- Keywords:
Ifosfamide;
Etoposide;
Carboplatin;
Small cell lung carcinoma
- MeSH:
Anemia;
Area Under Curve;
Carboplatin*;
Drug Therapy*;
Drug Therapy, Combination;
Etoposide*;
Humans;
Ifosfamide*;
Neutropenia;
Prospective Studies;
Small Cell Lung Carcinoma*;
Survival Rate;
Thrombocytopenia
- From:Korean Journal of Medicine
2006;70(6):688-694
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This prospective phase II study assessed the efficacy and toxicity of the combination of carboplatin, ifosfamide and etoposide for previously untreated patients with extensive-disease small cell lung cancer (ED-SCLC). METHODS: Patients with ED-SCLC received a combination chemotherapy with carboplatin AUC 6.0 on day 1, ifosfamide 1200 mg/m2 on day 1-3, and etoposide 100 mg/m2 on day 1-3. RESULTS: Forty-one patients received a median of six cycles of chemotherapy. A complete response was seen in 5 patients and a partial response was seen in 33 patients (overall response 95%). The median duration of the response was 5.1 months (95% CI; 3.4-6.8 months). The median time to progression and overall survival were 7.4 months (95% CI; 6.1-8.6 months) and 10.7 months (95% CI; 6.9-14.6 months), respectively, providing the one-year survival rate of 43.9%. Grade 3~4 anemia, neutropenia and thrombocytopenia occurred in 14%, 7% and 6% in a total of 212 cycles, respectively. Non-hematologic toxicities were generally mild and manageable. No treatment related death was observed. CONCLUSIONS: The combination chemotherapy of carboplatin, etoposide and ifosfamide showed an effective response rate and acceptable toxicity.
